Seki Lab

Personal Statement

Dr. Seki’s early research career focused on the study of Toll-like receptors in Kupffer cells. He then combined his immunology research background with the study of chronic liver diseases, including liver fibrosis, alcohol-associated liver disease (ALD), and nonalcoholic fatty liver disease (NAFLD).


Ekihiro Seki, MD, PhD

Our research team has reported that Toll-like receptors and intestine-derived bacterial products promote liver fibrosis and fatty liver disease (Seki, et al. Nat Med. 2007). More recently, we determined that hyaluronan (HA), a biomarker for liver cirrhosis, is the cause and can be a therapeutic target for liver fibrosis (Yang, et al. Sci Transl Med. 2019).

Collaborations

Meet Our Team

Learn more about the scientists, faculty members, investigators and other healthcare professionals of the Seki Laboratory, whose dedicated efforts lead to groundbreaking discoveries.

Yang YM, Noureddin M, Liu C, Ohashi K, Kim SY, Ramnath D, Powell EE, Sweet MJ, Roh YS, Hsin IF, Deng N, Liu Z, Liang J, Mena E, Shouhed D, Schwabe RF, Jiang D, Lu SC, Noble PW, Seki E.

Sci Transl Med. 2019;11(496). pii: eaat9284.

Ohashi K, Wang Z, Yang YM, Billet S, Tu W, Pimienta M, Cassel SL, Pandol SJ, Lu SC, Sutterwala FS, Bhowmick N, Seki E

Hepatology. 2019;70(5):1582-1599.

Liang S, Zhong Z, Kim SY, Uchiyama R, Roh YS, Matsushita H, Gottlieb RA, Seki E.

J Biol Chem. 2019;294(33):12359-12369.

Yang YM, Kim SY, Seki E.

Semin Liver Dis. 2019;39(1):26-42. Review.

Contact the Seki Lab

8700 Beverly Blvd.
Davis Building, Rooms 2099, 2029
Los Angeles, CA 90048